PDCD1 and nonpapillary renal cell carcinoma: The first-line treatment for ccRCC includes immunotherapy using programmed cell death 1 (PD-1) checkpoint inhibitors, such as nivolumab and pembrolizumab, combined with molecular targeted therapy.